Browsing by Subject "Xerostomia"

Now showing 1 - 2 of 2
  • Thumbnail Image
    Publication
    Embargo
    Salivary adiponectin, but not adenosine deaminase, correlates with clinical signs in women with Sjögren’s syndrome: a pilot study
    (https://link.springer.com/, 2018-07-20) Tvarijonaviciute, Asta; Zamora, Carmen; Martinez-Subiela, Silvia; Tecles, Fernando; Pina, Francisca; Lopez Jornet, Pia; Dermatología, Estomatología, Radiología y Medicina Física
    Objectives To evaluate salivary adiponectin and adenosine deaminase (ADA) in women suffering from Sjögren’s syndrome (SS). Methods Salivary adiponectin and ADA were measured in patients with SS (n = 17) and compared to their values in healthy controls (n = 13) and patients suffering from drug-induced xerostomia (non-SS sicca group; n = 19). A clinical history was made for each patient, patients were examined clinically, and xerostomia inventory (XI) was performed. Results Salivary adiponectin corrected by total protein was higher in patients with SS than in healthy individuals (P < 0.05) or patients with non-SS sicca (P < 0.01) and correlated with XI (r = 0.555; P < 0.05). Salivary ADAwas higher in patients with SS and non-SS sicca compared to controls (P<0.05 in both cases). Conclusion The results of the present study indicate that adiponectin and ADA are increased in the saliva of patients with SS. Clinical relevance Salivary adiponectin corrected by total protein can be a potential biomarker of SS.
  • Thumbnail Image
    Publication
    Embargo
    Salivary adiponectin, but not adenosine deaminase, correlates with clinical signs in women with Sjögren's syndrome: a pilot study
    (2019-03) López Jornet, María Pía; Tvarijonaviciute, Asta; Zamora, Carmen; Martinez Subiela, Silvia; Tecles, Fernando; Pina, Francisca; Dermatología, Estomatología, Radiología y Medicina Física
    Abstract Objectives: To evaluate salivary adiponectin and adenosine deaminase (ADA) in women suffering from Sjögren's syndrome (SS). Methods: Salivary adiponectin and ADA were measured in patients with SS (n = 17) and compared to their values in healthy controls (n = 13) and patients suffering from drug-induced xerostomia (non-SS sicca group; n = 19). A clinical history was made for each patient, patients were examined clinically, and xerostomia inventory (XI) was performed. Results: Salivary adiponectin corrected by total protein was higher in patients with SS than in healthy individuals (P < 0.05) or patients with non-SS sicca (P < 0.01) and correlated with XI (r = 0.555; P < 0.05). Salivary ADA was higher in patients with SS and non-SS sicca compared to controls (P < 0.05 in both cases). Conclusion: The results of the present study indicate that adiponectin and ADA are increased in the saliva of patients with SS. Clinical relevance: Salivary adiponectin corrected by total protein can be a potential biomarker of SS. Trial registration: NCT03156569.